FMI - Foundation Medicine, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
136.40
-0.05 (-0.04%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close136.45
Open136.40
Bid135.90 x 1000
Ask136.55 x 1800
Day's Range136.35 - 136.50
52 Week Range31.70 - 137.20
Volume1,164,228
Avg. Volume473,420
Market Cap5.052B
Beta1.63
PE Ratio (TTM)N/A
EPS (TTM)-4.21
Earnings DateJul 30, 2018 - Aug 3, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est80.75
Trade prices are not sourced from all markets
  • Company News For Jun 20, 2018
    Zacks2 days ago

    Company News For Jun 20, 2018

    Companies in the news are: T,FMI,COTV,SRPT

  • ACCESSWIRE2 days ago

    Today’s Research Reports on Stocks to Watch: Foundation Medicine and Solid Biosciences

    NEW YORK, NY / ACCESSWIRE / June 20, 2018 / Shares of Foundation Medicine exploded on Tuesday after announcing that it has entered into a definitive merger agreement for Roche to acquire the outstanding shares of FMI`s common stock not already owned by Roche and its affiliates at a price of US$ 137.00 per share. Shares of Solid Biosciences also broke out after announcing that the FDA has lifted a clinical hold on the company's phase I/II trial, IGNITE DMD, for its experimental candidate, SGT-001. Foundation Medicine, Inc. shares closed up 28.46% on Tuesday, with about 6.3 million shares traded compared to an average trading volume of about 409,00 shares.

  • Roche to Buy Rest of Foundation Medicine for $2.4 billion
    Zacks2 days ago

    Roche to Buy Rest of Foundation Medicine for $2.4 billion

    Roche inks a deal with Foundation Medicine to acquire the remaining shares of Foundation Medicine, not already owned by it for a total consideration of $2.4 billion.

  • Financial Times2 days ago

    [$$] Jefferies’ great leap forward on Wall Street

    Buyout fund CVC is in advanced talks to acquire a majority stake in the pharmaceutical group owned by Italy’s billionaire Recordati family. Over the past 20 years Jefferies has pulled clear of the Wall Street pack of boutique investment banks, making leaps ahead of its rivals, which include the likes of Oppenheimer, SG Cowen, Piper Jaffray, Thomas Weisel Partners and William Blair. Profits at the Madison Avenue-based investment bank jumped 41 per cent for the three months ending on May 31.

  • The Wall Street Journal2 days ago

    [$$] Roche to Pay $2.4 Billion for Full Control of Foundation Medicine

    Roche Holding AG on Tuesday said it would pay $2.4 billion to buy the shares it doesn’t already own in Foundation Medicine Inc., furthering its bet on personalized cancer care. The Swiss drug giant, which already owns roughly 57% of Foundation, will pay $137 a share for the U.S.-based company, valuing it at $5.3 billion. Cambridge, Mass.-based Foundation makes molecular-diagnostic tests that identify alterations in a patient’s cancer.

  • PR Newswire2 days ago

    WeissLaw LLP: Foundation Medicine, Inc. Acquisition May Not Be In The Best Interest of FMI Shareholders

    NEW YORK , June 19, 2018 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Foundation Medicine, Inc. ("FMI" ...

  • Why CVS Health, Foundation Medicine, and Solid Biosciences Jumped Today
    Motley Fool3 days ago

    Why CVS Health, Foundation Medicine, and Solid Biosciences Jumped Today

    Find out why healthcare made a big leap in today's market action.

  • How A Merger Will Help These Two Firms Tailor Cancer Treatments
    Investor's Business Daily3 days ago

    How A Merger Will Help These Two Firms Tailor Cancer Treatments

    Foundation Medicine rocketed to a record high Tuesday after Swiss drugmaker Roche agreed to buy it in a pharmaceutical merger for $2.4 billion.

  • Roche Does Pharma M&A Without the Pharma
    Bloomberg3 days ago

    Roche Does Pharma M&A Without the Pharma

    The Swiss giant agreed Tuesday to pay $2.4 billion to buy out the remaining shareholders in Foundation Medicine Inc., a cancer-focused gene sequencing company in which it holds a more than 50 percent stake. It follows Roche's $1.9 billion purchase earlier this year of Flatiron Health Inc., which collects and analyzes real-world data on how cancer patients are treated. These were Roche’s two biggest deals since 2014. The Foundation deal comes at a hefty premium, and may be a disappointment to investors who would have preferred a more typical acquisition focused on an actual, existing drug.

  • Why Foundation Medicine Stock Is Skyrocketing 28.3% Higher Today
    Motley Fool3 days ago

    Why Foundation Medicine Stock Is Skyrocketing 28.3% Higher Today

    The company's being acquired by long-time partner Roche Holdings.

  • Netflix expands, Amazon teams up with Marriott, Wells Fargo merging wealth management groups
    Yahoo Finance3 days ago

    Netflix expands, Amazon teams up with Marriott, Wells Fargo merging wealth management groups

    Netflix, Amazon, Wells Fargo, Roche and Apple are the companies to watch.

  • Stocks fall deep into the red as trade war escalates
    Yahoo Finance3 days ago

    Stocks fall deep into the red as trade war escalates

    Yahoo Finance's LIVE market coverage and analysis of what you need to watch in the stock market begins each day at 9:25 a.m. ET.

  • The Wall Street Journal3 days ago

    [$$] European Corporate Roundup for Tuesday

    A $2.4 billion Roche acquisition and another Debenhams profit warning are the European corporate highlights Tuesday.

  • Roche pays $2.4 billion for rest of cancer expert Foundation Medicine
    Reuters3 days ago

    Roche pays $2.4 billion for rest of cancer expert Foundation Medicine

    ZURICH/LONDON (Reuters) - Swiss drugmaker Roche is paying $2.4 billion to buy the rest of Foundation Medicine (FMI), raising its bet on the U.S. genomic profiling group's ability to personalise cancer care. The deal, backed by the boards of both companies, is worth $137 per share - a premium of 29 percent to FMI's closing price on Monday - valuing the Cambridge, Massachusetts-based company at $5.3 billion. It is the latest in a series of bolt-on acquisitions by Roche as the world's largest marker of cancer drugs seeks to tap into promising technology developed by biotech companies to drive future growth as its older drugs face competition.

  • The Wall Street Journal3 days ago

    [$$] Roche to Buy Rest of Foundation Medicine

    The Swiss drug giant, which already owns roughly 57% of Foundation, will pay $137 a share for the U.S.-based company, valuing it at $5.3 billion. Cambridge, Mass.-based Foundation makes molecular-diagnostic tests that identify alterations in a patient’s cancer. The deal to take full control of Foundation comes after Roche first bought a stake in the company in 2015.

  • Roche pays $2.4 billion for rest of cancer expert Foundation Medicine
    Reuters3 days ago

    Roche pays $2.4 billion for rest of cancer expert Foundation Medicine

    ZURICH/LONDON (Reuters) - Swiss drugmaker Roche (ROG.S) is paying $2.4 billion to buy the rest of Foundation Medicine (FMI) (FMI.O), raising its bet on the U.S. genomic profiling group's ability to personalize cancer care. The deal, backed by the boards of both companies, is worth $137 per share - a premium of 29 percent to FMI's closing price on Monday - valuing the Cambridge, Massachusetts-based company at $5.3 billion. It is the latest in a series of bolt-on acquisitions by Roche as the world's largest marker of cancer drugs seeks to tap into promising technology developed by biotech companies to drive future growth as its older drugs face competition.

  • GlobeNewswire3 days ago

    Roche and Foundation Medicine reach definitive merger agreement to accelerate broad availability of comprehensive genomic profiling in oncology

    OTCQX: RHHBY) and Foundation Medicine, Inc. (FMI) today announced they have entered into a definitive merger agreement for Roche to acquire the outstanding shares of FMI`s common stock not already owned by Roche and its affiliates at a price of US$ 137.00 per share in cash. This corresponds to a total transaction value of US$ 2.4 billion on a fully diluted basis, and a total company value of US$ 5.3 billion on a fully diluted basis.

  • Financial Times3 days ago

    [$$] Roche to spend $2.4bn buying rest of Foundation Medicine

    is to spend $2.4bn buying out remaining shareholders in Foundation Medicine, a US molecular and genomic analysis company in which it took a controlling stake three years ago. The deal, announced on Tuesday, aims to strengthen Roche’s development of personalised cancer therapies as the Swiss group looks for new growth areas to compensate for the loss of exclusivity on long-time blockbuster drugs.

  • Financial Times3 days ago

    [$$] Genomics/Roche: precision vision

    “The most wondrous map ever produced by humankind.” That was how US president Bill Clinton described the newly sequenced human genome in 2000. Now dream and reality are converging in a flurry of multibillion bets on the end to the “one size fits all” approach to cancer treatment. of the 43 per cent of Foundation Medicine it does not own.

  • Business Wire17 days ago

    Foundation Medicine to Present at Upcoming Investor Conferences

    Foundation Medicine (FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials.

  • 5 Top Performing Stocks of the Best ETF of May
    Zacks22 days ago

    5 Top Performing Stocks of the Best ETF of May

    Inside the best performing stocks of the top ETF of May - ARKG.

  • Business Wire24 days ago

    Foundation Medicine and Collaborators to Present New Data at ASCO 2018 Supporting Comprehensive Genomic Profiling (CGP) to Inform Personalized Approaches in Cancer Care

    Foundation Medicine, Inc. today announced that new data generated from its comprehensive genomic profiling assays will be presented at the American Society of Clinical Oncology Annual Meeting from June 1-5, 2018 in Chicago.

  • Mattel, Foundation Medicine and Sirius are the Yahoo Finance Charts of the day.
    Yahoo Finance Video3 days ago

    Mattel, Foundation Medicine and Sirius are the Yahoo Finance Charts of the day.

    Let's check out the Yahoo Finance charts of the day. Mattel (MAT): Shares are down in early trade, at around 2.9%.  The toy maker was downgraded to "neutral" from "buy" at UBS, which still sees value in the brand but notes the stock's 35 percent jump from its March lows despite little change in fundamentals. Foundation Medicine (FMI): Shares up here, around 28.5%.  Roche Holding said it would pay $2.4 billion to buy the shares it doesn't already own in Foundation Medicine. The Swiss drug giant presently owns 57% of Foundation and will pay $137 a share for the U.S based company. Sirius (SIRI): Shares down here, at around 1.7%. The satellite radio operator was downgraded to "hold" from "buy" at Pivotal Research in a valuation call. Pivotal's target price for the Sirius stock remains at $7.75 per share. For more on today's big stock movers check out the Final Round, live at 3:55 p.m. ET, right here on Yahoo Finance.

  • Netflix expands and has price target raised, Amazon teams up with Marriott hotels, Wells Fargo merging wealth management groups
    Yahoo Finance Video3 days ago

    Netflix expands and has price target raised, Amazon teams up with Marriott hotels, Wells Fargo merging wealth management groups

    Netflix, Amazon, Wells Fargo, Roche and Apple are the companies to watch.